Vyriad

Executive Summary

Vyriad is a privately held biotechnology company headquartered in Rochester, Minnesota, founded in 2014. The company specializes in engineering targeted virus platforms for therapeutic delivery, with a primary focus on developing durable in vivo gene therapies, genome editing tools, and oncolytic virotherapies to treat diseases, particularly cancer. Leveraging a collaborative, end-to-end approach from research through clinical development, Vyriad aims to overcome key limitations of existing viral vectors, including immunogenicity and payload capacity, to enable safer and more effective treatments. With a team of 51-200 employees, the company operates at the preclinical stage, emphasizing innovation in viral technology.

Upcoming Catalysts (preview)

• Q2 2027IND filing for lead oncolytic virotherapy candidate65% success
• Q4 2026Strategic partnership with a major pharmaceutical company for gene therapy platform40% success
• Q1 2027Publication of preclinical data demonstrating durable gene expression in a key indication80% success